NeuroPace, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NPCE research report →
Range $12 – $21
Price Chart
About the company
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
- CEO
- Joel D. Becker
- IPO
- 2021
- Employees
- 216
- HQ
- Mountain View, CA, US
Get TickerSpark's AI analysis on NPCE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $273.89M
- P/E
- -14.65
- Fwd P/E
- 318.00
- PEG
- -0.47
- P/S
- 3.00
- P/B
- 24.60
- EV/EBITDA
- -31.04
- Div Yield
- 0.00%
- Gross Margin
- 81.41%
- Op Margin
- -15.39%
- Net Margin
- -20.00%
- ROE
- -133.07%
- ROIC
- -17.97%
Latest fiscal year · YoY change
- Revenue
- $99.99M+25.1%
- Gross Profit
- $77.22M+30.7%
- Op Income
- $-16,338,000
- Net Income
- $-21,465,000+20.9%
- EPS
- $-0.66+29.0%
- OCF Growth
- +38.7%
- FCF Growth
- +37.9%
- 52W High
- $19.60
- 52W Low
- $5.46
- 50D MA
- $12.57
- 200D MA
- $14.57
- Beta
- 1.93
- RSI (14)
- 26
- Avg Volume
- 270.76K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
NeuroPace’s Q3 revenue missed expectations as large-account disruption, sales-force changes, and SEEG transition effects weighed on performance, but management kept a constructive long-term outlook tied to execution improvements and multiple growth catalysts.· November 12, 2026
- Q3 total revenue was $23.1 million; RNS System revenue was $22.9 million, up about 1% year over year, but management said the quarter fell well short of expectations.
- Adjusted gross margin improved to 84.8% from 82.8% a year ago, while adjusted EBITDA turned positive at $0.4 million.
- The company cut 2026 guidance: total revenue now $91 million to $92 million versus $99.5 million to $101.5 million previously, with RNS revenue of $90 million to $91 million.
- Management said several headwinds were transient: operational issues at a few large accounts, disruption from sales-organization changes, and lingering effects from exiting SEEG distribution.
- NeuroPace kept its 2027 growth framework intact, calling for roughly 15% full-year RNS revenue growth, with acceleration in the back half of 2027 and no IGE contribution included.
Third-quarter 2026 total revenue was $23.1 million, down 1.1% from $23.4 million a year ago. RNS System revenue was $22.9 million, up 1.4% year over year from $22.6 million, and service revenue was $203,000 versus $771,000 last year. Adjusted gross margin was 84.8% versus 82.8% in the prior-year period, and GAAP gross margin from continuing operations was 84.3%. Adjusted operating expenses were $19.2 million, down about 7% year over year; adjusted operating income was $0.4 million, adjusted net loss was $0.9 million, and adjusted EBITDA was a gain of $0.4 million. Cash, cash equivalents, short-term investments and restricted cash totaled $49.5 million at quarter-end, and long-term borrowings were $59.2 million. For 2026, management guided to total revenue of $91 million to $92 million, including about $90 million to $91 million of RNS revenue; adjusted gross margin is expected at 83% to 83.5%, adjusted operating expenses at $85 million to $86 million, and adjusted EBITDA loss at $8.5 million to $9.5 million. For 2027, management said it currently expects about 15% full-year RNS revenue growth, with first-half growth of 10% to 15% and second-half growth of 15% to 20%, excluding any contribution from IGE and excluding service revenue.
Joel Becker was candid that Q3 was a disappointment and repeatedly took accountability for the miss. His strategic message was that the business still has strong underlying demand, but execution needs to improve through better commercial coverage, stronger referral pathways, and more consistent planning. He framed the quarter as a reset around scaling for future catalysts, including IGE, adolescent focal epilepsy, Remote Care, and broader product innovation, while stressing that management believes the RNS growth opportunity remains substantial.
Patrick Williams focused on the financial reset and the path back to growth. He cited $23.1 million of total revenue, 84.8% adjusted gross margin, $19.2 million of adjusted operating expenses, and $0.4 million of adjusted EBITDA, then noted the stronger-than-expected margin performance helped lift the full-year gross margin outlook to 83% to 83.5%. He also said spending is being tightened, with 2026 adjusted operating expenses now expected at $85 million to $86 million, down from $90 million to $92 million previously, and reiterated the company is balancing investment in commercial and R&D priorities with financial discipline.
Analysts pressed management on whether the company can return to 20% RNS growth, how much of the Q3 miss came from the sales-force overhaul versus account-specific issues, and whether the SEEG exit permanently hurt access to key neurosurgeons. Management said it believes there is still a path back to 20% growth, but that it will take time and additional investment; it also said most of the large-account disruption was transient, patients were largely pushed out rather than lost, and the sales reorganization did not appear to have caused permanent account loss. On FDA and pipeline questions, management said the IGE amendment is on track for a submission around year-end, that the FDA discussion centered on requested statistical analyses, and that AURORA for adolescent focal epilepsy is being pursued through a collaborative real-world-evidence approach.
The call still pointed to a durable long-term growth story if execution improves. Management said active prescribers reached a new high, larger-account disruptions appear to be recovering, and 2027 could bring multiple catalysts including Remote Care, IGE, and adolescent focal epilepsy. Gross margin was strong, and the company believes its commercial fixes plus a broader account base can restore growth.
The near-term picture is weaker: Q3 missed expectations, 2026 revenue guidance was cut materially, and management is not assuming a quick snapback in Q4. The business appears sensitive to customer concentration, and disruptions at a few large accounts had an outsized impact. In addition, the company acknowledged that the sales-organization changes created disruption, and the timing of regulatory and product catalysts remains dependent on FDA review and future data.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 73.7%
- Shares Outstanding
- 34.45M
- Float Shares
- 25.39M
of shares held by institutions
115 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| First Light Asset Management, LLC | 3.98M | ▲ 1.12M |
| Polar Capital Holdings PLC | 3.30M | 0 |
| Soleus Capital Management, L.P. | 3.22M | ▲ 306.88K |
| Morgan Stanley | 2.57M | ▼ 85.52K |
| Blackrock, Inc. | 2.47M | ▼ 10.10K |
| Vanguard Group Inc | 1.48M | ▲ 46.38K |
| Driehaus Capital Management LLC | 1.43M | ▼ 17.95K |
| Vanguard Capital Management LLC | 1.23M | ▲ 7.10K |
| Orbimed Advisors LLC | 1.06M | ▼ 450.00K |
| Deutsche Bank AG\ | 935.65K | ▼ 3.27K |
| Armistice Capital, LLC | 800.00K | ▲ 108.00K |
| Geode Capital Management, LLC | 662.19K | ▼ 4.11K |
Held by 142 ETFs
Biggest fund positions in NPCE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Huennekens R Scott | buy | 12,500 |
| Nov 17, 26 | Williams Patrick F. | buy | 11,891 |
| Nov 17, 26 | Becker Joel | buy | 11,891 |
| Sep 24, 26 | Morrell Martha | other | 335 |
| Sep 20, 26 | Williams Patrick F. | other | 1,162 |
| Sep 3, 26 | Becker Joel | other | 1,310 |
| Aug 27, 26 | Becker Joel | other | 1,126 |
| Aug 27, 26 | Morrell Martha | other | 358 |
| Jun 24, 26 | Morrell Martha | other | 335 |
| Jun 19, 26 | Geiger Uri | other | 789 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NPCE coverage
Recent articles, reports, and earnings notes.
No research on NPCE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NPCE report →NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with SBS Law
businesswire.com · Nov 21
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
zacks.com · Nov 19
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving NeuroPace (NPCE)
globenewswire.com · Nov 19
NEUROPACE, INC. INVESTIGATION: NPCE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
businesswire.com · Nov 17
Is NPCE Worth Buying Now as Growth Potential Meets Execution Risk?
zacks.com · Nov 17
NeuroPace Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into NeuroPace (NPCE)
prnewswire.com · Nov 16
What NeuroPace (NPCE) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
NeuroPace, Inc. (NPCE) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.